Neoprobe (NEOP) jumps 4.5% AH after announcing it has licensed worldwide exclusive rights to...

|By:, SA News Editor

Neoprobe (NEOP) jumps 4.5% AH after announcing it has licensed worldwide exclusive rights to AstraZenaca's (AZN) AZD4694 patient imaging solution, and plans to initiate Phase III trials in early 2013. Neoprobe will pay AstraZanaca a $5M up-front licensing fee, as well as future milestone payments and royalties.